mAb-话题@MedSci

#mAb#

1302篇内容 | 2304人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912540, encodeId=bf6d19125408e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=长效双特异性抗体faricimab用于特定黄斑变性和糖尿病性黄斑水肿，4个月注射一次，效果出色, objectType=article, longId=207129, objectId=d13920e12909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d13920e12909, replyNumber=0, likeNumber=63, createdTime=2021-03-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d13920e12909, moduleTitle=长效双特异性抗体faricimab用于特定黄斑变性和糖尿病性黄斑水肿，4个月注射一次，效果出色, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d13920e12909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912560, encodeId=640b1912560a3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Eur Urol Oncol：新辅助Atezolizumab在接受根治性膀胱切除术的肌肉侵袭性膀胱癌患者中的毒性和手术并发症发生率, objectType=article, longId=207866, objectId=29cc20e866f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29cc20e866f0, replyNumber=0, likeNumber=64, createdTime=2021-12-23, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29cc20e866f0, moduleTitle=Eur Urol Oncol：新辅助Atezolizumab在接受根治性膀胱切除术的肌肉侵袭性膀胱癌患者中的毒性和手术并发症发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29cc20e866f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912643, encodeId=c79b19126431a, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。, objectType=article, longId=213761, objectId=ae12213e61f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae12213e61f4, replyNumber=0, likeNumber=94, createdTime=2021-10-29, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae12213e61f4, moduleTitle=Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae12213e61f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912587, encodeId=b5af191258e41, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=安进创新胃癌一线疗法bemarituzumab获美国FDA突破性疗法认定, objectType=article, longId=210265, objectId=27f521026528, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27f521026528, replyNumber=0, likeNumber=49, createdTime=2022-01-28, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27f521026528, moduleTitle=安进创新胃癌一线疗法bemarituzumab获美国FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27f521026528)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912599, encodeId=c6c11912599c8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性, objectType=article, longId=211247, objectId=676f21124ed8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676f21124ed8, replyNumber=0, likeNumber=94, createdTime=2021-05-14, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676f21124ed8, moduleTitle=J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676f21124ed8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912657, encodeId=4322191265e53, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150, objectType=article, longId=214763, objectId=e0a7214e632f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0a7214e632f, replyNumber=0, likeNumber=71, createdTime=2022-01-31, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0a7214e632f, moduleTitle=J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0a7214e632f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912555, encodeId=8eae1912555b1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见, objectType=article, longId=207706, objectId=989b20e706d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989b20e706d8, replyNumber=0, likeNumber=74, createdTime=2021-06-11, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989b20e706d8, moduleTitle=Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989b20e706d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912544, encodeId=e5c71912544c4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, objectType=article, longId=207196, objectId=04c620e196a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04c620e196a7, replyNumber=0, likeNumber=70, createdTime=2021-11-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04c620e196a7, moduleTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04c620e196a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912422, encodeId=2ddc1912422a3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Eisai和Biogen正在向FDA申请aducanumab治疗阿尔茨海默症的优先审查, objectType=article, longId=199065, objectId=9d351990652f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d351990652f, replyNumber=0, likeNumber=69, createdTime=2020-08-12, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d351990652f, moduleTitle=Eisai和Biogen正在向FDA申请aducanumab治疗阿尔茨海默症的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d351990652f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912494, encodeId=9b0b1912494fd, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NICE指南支持isatuximab治疗多发性骨髓瘤（MM）, objectType=article, longId=203866, objectId=3f4520386600, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4520386600, replyNumber=0, likeNumber=88, createdTime=2021-03-31, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4520386600, moduleTitle=NICE指南支持isatuximab治疗多发性骨髓瘤（MM）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f4520386600)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912434, encodeId=fa1f191243414, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Leronlimab（PRO 140）治疗重度COVID-19：III期试验进展顺利, objectType=article, longId=199957, objectId=e37819995e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e37819995e34, replyNumber=0, likeNumber=50, createdTime=2021-06-18, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e37819995e34, moduleTitle=Leronlimab（PRO 140）治疗重度COVID-19：III期试验进展顺利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e37819995e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912476, encodeId=ce7b19124e617, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lenzilumab治疗COVID-19住院患者的III期临床：已取得阳性中期数据, objectType=article, longId=203078, objectId=c59e2030e858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c59e2030e858, replyNumber=0, likeNumber=85, createdTime=2021-03-12, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c59e2030e858, moduleTitle=Lenzilumab治疗COVID-19住院患者的III期临床：已取得阳性中期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c59e2030e858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912652, encodeId=e32219126524d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：bamlanivimab-etesevimab双中和抗体疗法治疗轻中度新冠肺炎, objectType=article, longId=214302, objectId=2dec214302a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dec214302a8, replyNumber=0, likeNumber=60, createdTime=2021-11-14, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dec214302a8, moduleTitle=NEJM：bamlanivimab-etesevimab双中和抗体疗法治疗轻中度新冠肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dec214302a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912505, encodeId=c8ca19125052b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=美国肾脏护理（USRC）将在透析门诊对COVID-19患者进行单克隆抗体（Bamlanivimab）治疗, objectType=article, longId=205041, objectId=b2e520504164, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2e520504164, replyNumber=0, likeNumber=84, createdTime=2021-06-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2e520504164, moduleTitle=美国肾脏护理（USRC）将在透析门诊对COVID-19患者进行单克隆抗体（Bamlanivimab）治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2e520504164)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912597, encodeId=71c2191259e86, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果, objectType=article, longId=211056, objectId=5c43211056a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c43211056a3, replyNumber=0, likeNumber=93, createdTime=2021-06-04, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c43211056a3, moduleTitle=Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c43211056a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912520, encodeId=30c8191252052, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤, objectType=article, longId=206006, objectId=dea22060068e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dea22060068e, replyNumber=0, likeNumber=115, createdTime=2021-03-17, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dea22060068e, moduleTitle=Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dea22060068e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912481, encodeId=e3eb1912481a9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=礼来的中和抗体bamlanivimab获得FDA紧急使用授权，用于治疗轻中度新冠COVID-19感染患者, objectType=article, longId=203247, objectId=649f20324ef1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649f20324ef1, replyNumber=0, likeNumber=53, createdTime=2021-04-29, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649f20324ef1, moduleTitle=礼来的中和抗体bamlanivimab获得FDA紧急使用授权，用于治疗轻中度新冠COVID-19感染患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649f20324ef1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912435, encodeId=b37119124357e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ESMO 2020：抗体-药物偶联物Tisotumab vedotin治疗复发宫颈癌取得积极进展, objectType=article, longId=199963, objectId=5ce5199963fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ce5199963fc, replyNumber=0, likeNumber=50, createdTime=2020-10-17, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ce5199963fc, moduleTitle=ESMO 2020：抗体-药物偶联物Tisotumab vedotin治疗复发宫颈癌取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ce5199963fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912614, encodeId=8ad119126144e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JCO：Gemtuzumab Ozogamicin可改善KMT2A重排型AML患儿预后、减少复发！, objectType=article, longId=212166, objectId=c8ad21216642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ad21216642, replyNumber=0, likeNumber=53, createdTime=2021-07-21, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ad21216642, moduleTitle=JCO：Gemtuzumab Ozogamicin可改善KMT2A重排型AML患儿预后、减少复发！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8ad21216642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912586, encodeId=e03e19125864e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JCC：乌司奴单抗（Ustekinumab）在溃疡性结肠炎中的有效性和安全性分析, objectType=article, longId=210176, objectId=e40e2101e64c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e40e2101e64c, replyNumber=0, likeNumber=114, createdTime=2022-01-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e40e2101e64c, moduleTitle=JCC：乌司奴单抗（Ustekinumab）在溃疡性结肠炎中的有效性和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e40e2101e64c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

长效双特异性抗体faricimab用于特定黄斑变性和糖尿病性黄斑水肿，4个月注射一次，效果出色

2021-03-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Eur Urol Oncol：新辅助Atezolizumab在接受根治性膀胱切除术的肌肉侵袭性膀胱癌患者中的毒性和手术并发症发生率

2021-12-23

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。

2021-10-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

安进创新胃癌一线疗法bemarituzumab获美国FDA突破性疗法认定

2022-01-28

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Immunother Cancer：PD1抑制剂联合ipilimumab在伴有自身免疫疾病晚期黑素色瘤患者的疗效与安全性

2021-05-14

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150

2022-01-31

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见

2021-06-11

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）

2021-11-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Eisai和Biogen正在向FDA申请aducanumab治疗阿尔茨海默症的优先审查

2020-08-12

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NICE指南支持isatuximab治疗多发性骨髓瘤（MM）

2021-03-31

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Leronlimab（PRO 140）治疗重度COVID-19：III期试验进展顺利

2021-06-18

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lenzilumab治疗COVID-19住院患者的III期临床：已取得阳性中期数据

2021-03-12

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：bamlanivimab-etesevimab双中和抗体疗法治疗轻中度新冠肺炎

2021-11-14

snf701207 (审核中...)

前往app查看评论内容

#mAb#

美国肾脏护理（USRC）将在透析门诊对COVID-19患者进行单克隆抗体（Bamlanivimab）治疗

2021-06-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果

2021-06-04

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤

2021-03-17

snf701207 (审核中...)

前往app查看评论内容

#mAb#

礼来的中和抗体bamlanivimab获得FDA紧急使用授权，用于治疗轻中度新冠COVID-19感染患者

2021-04-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ESMO 2020：抗体-药物偶联物Tisotumab vedotin治疗复发宫颈癌取得积极进展

2020-10-17

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JCO：Gemtuzumab Ozogamicin可改善KMT2A重排型AML患儿预后、减少复发！

2021-07-21

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JCC：乌司奴单抗（Ustekinumab）在溃疡性结肠炎中的有效性和安全性分析

2022-01-27

科室
- - 订阅+
  - 更多科室
工具
服务